Tabituximab barzuxetan Yttrium Y-90

N/A

Report date: 2025/10/20 14:43:44

Base Information

Drug NameTabituximab barzuxetan Yttrium Y-90

Drug Alias NamehFz10 antibodiesTT641 pAbYttrium 90-radiolabelled OTSA 101DTPA-90YOTSA-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionWnt signalling pathway inhibitorsAnti-FZD10

TargetsFrizzled-10

Therapy Area/IndicationsSarcoma, Synovial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFranceJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOncotherapy Science, Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOncotherapy Science, Inc

Active IndicationsN/A

Inactive IndicationsSarcoma, Synovial

Other Information

ATC CodeN/A